A bispecific antibody
is a second generation immunotherapy, an upgraded version of monoclonal antibody improved in structure and functionality.
Antibody technologies: Chimeric, fully human, humanized, pegylation, Fab fragment, Fc engineering, glycoengineering, antibody drug conjugate (ADC), bispecific antibody
, naked antibody, pretargeted radioimmmunotherapy (PT-RAIT), cell-killing agents, cytotoxic agent, toxin, tumor-targeted superantigens (TTS), antibody-dependent cell-mediated cytotoxicity (ADCC) enhancing, complement-dependent cytotoxicity (CDC) enhancing, inhibiting and activating Fc receptors, defucosylation, isotype chimerism, production systems, glycosidase inhibitors, sugar engineering, Fab arm switching or Fab crossover, trifunctional, bispecific T cell engager (BiTE), dual-variable-domain immunoglobulin (DVD-Ig), TandAb, dock and lock (DNL) technology, dual-affinity re-targeting (DART).
We have also selected our second bispecific antibody
, XmAb13676, which will enter clinical testing for B-cell malignancies in 2016.
th] Congress of the European Hematology Association in Amsterdam Professor Max Topp of the University of Wuerzberg in Germany presents the impressive results with a bispecific antibody
for Acute Lymphoblastic Leukemia patients.
Jack Barbut, CEO, commented that 'with the external validation through the Genentech/Roche deal this summer, the current financing round allows NovImmune to generate Proof-of-Concept data with at least two compounds, increase the number of partnerships, and complete the validation of its proprietary bispecific antibody
generation platform (kappa-lambdabodies[TM]).
I have known Sergej since he was a researcher at the German Cancer Research Center (DKFZ), Heidelberg, Germany, playing a key role in creating novel bispecific antibody
formats for use in tumor therapy.
securities laws, including quotations from the Company's president and chief executive officer and other statements associated with Xencor's research, collaborations and its expectations regarding future therapeutic and commercial potential of Xencor's technologies, programs, drug candidates, including XmAb5871, XmAb7195, XmAb14045 and its bispecific antibody
development pipeline, and intellectual property related to Xencor's XmAb technology.
Treatment would begin with injection of a bispecific antibody
that targets the cancer.
The company has made significant advances in developing human monoclonal antibodies, complemented by comprehensive and fully integrated bispecific antibody
and antibody drug conjugate (ADC) platforms that include proprietary conjugation chemistries, linkers and toxic payloads.
Preclinical presentations include a late breaking abstract on the impact of MM-121, an ErbB3-targeting antibody, on chemosensitivity in heregulin-stimulated tumor cell models, a poster on the mechanism of MM-131, a novel bispecific antibody
targeting the c-Met pathway, and a poster on the effect of MM-302 on breast cancer tumor models with intermediate levels of HER2.
In December 2014, Xencor presented at the American Society of Hematology (ASH) Annual Meeting preclinical results from its three bispecific antibody
programs, which demonstrated that targeting CD3 together with each of CD123, CD20 and CD38 antigens activated T-cells to rapidly kill target cells from a single dose IV bolus in cynomolgus monkeys and demonstrated prolonged half-life of approximately one week in mice.
The report covers bispecific antibody
drugs currently available in the market as well as in various stages of clinical trials.